(redirected from AA amyloidosis)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to AA amyloidosis: AL amyloidosis, reactive amyloidosis


Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.


(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism


n. amiloidosis, acumulación de amiloide en los tejidos.


n amiloidosis f
References in periodicals archive ?
sup][5] According to the disease course, our patient is most likely had AA amyloidosis resulted from chronic inflammation of SSc.
The most common forms of amyloidosis include systemic AL amyloidosis (formerly primary amyloidosis), systemic AA amyloidosis (formerly secondary amyloidosis), systemic wild-type ATTR amyloidosis (formerly age-related or senile systemic amyloidosis), systemic hereditary ATTR amyloidosis (formerly familial amyloid polyneuropathy), and localized AL amyloidosis (Table 1).
1) A significant association between chronic inflammatory states and fatal AA amyloidosis has also been described in falcons (Falco species) of the Middle East.
AA amyloidosis can complicate a number of chronic inflammatory conditions, including rheumatoid arthritis (RA), juvenile RA, and ankylosing spondylitis1,2.
Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras Colchicine treatment of AA amyloidosis of familial Mediterranean fever.
KIACTA(TM) is being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis.
Half of all patients diagnosed with AA amyloidosis die within five years of diagnosis.
In conclusion, this case illustrates a phenotypic shift in a renal transplant patient with unrecognized FMF and secondary AA amyloidosis possibly due to the newly established equilibrium in various cytokines with ongoing immunosuppression.
3) The authors did not describe clearly whether their classification is suitable for this particular form of renal AA amyloidosis.
Snow's presentation is: "Marked Removal and Clearance of AA Amyloid Deposits in Target Organs (Kidney, Liver and Spleen) by the Small Molecule Systebryl(TM) Following Oral Administration: A Potential Break-through Drug for the Treatment of Systemic AA Amyloidosis.